

Jimmi Nielsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7118191/publications.pdf>

Version: 2024-02-01

59
papers

2,970
citations

186265

28
h-index

168389

53
g-index

60
all docs

60
docs citations

60
times ranked

3583
citing authors

#	ARTICLE	IF	CITATIONS
1	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
2	Use of psychotropic medication and risk of road traffic crashes: a registry-based caseâ€“control study in Denmark, 1996â€“2018. <i>Psychopharmacology</i> , 2022, 239, 2537-2546.	3.1	7
3	Clozapine and mortality: A comparison with other antipsychotics in a nationwide Danish cohort study. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 216-226.	4.5	16
4	Use of methylphenidate and the incidence of intentional self-harm or suicide attempts among individuals with schizophrenia, bipolar disorder and personality disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 422-424.	2.3	1
5	Elevated levels of soluble urokinase plasminogen activator receptor as a low-grade inflammation marker in schizophrenia: A case-control study. <i>Schizophrenia Research</i> , 2021, 228, 190-192.	2.0	3
6	Clozapine treatment in a wider context: From before eligibility to life beyond clozapine. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 419-421.	4.5	1
7	Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms. <i>BMC Psychiatry</i> , 2021, 21, 527.	2.6	4
8	T10. BIOMARKERS IN TREATMENT-RESISTANT SCHIZOPHRENIA; THE BITS STUDY (A STUDY PROTOCOL). <i>Schizophrenia Bulletin</i> , 2020, 46, S234-S235.	4.3	0
9	The use of stimulants in depression: Results from a self-controlled register study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 808-817.	2.3	9
10	Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey. <i>Schizophrenia Research</i> , 2019, 211, 105-107.	2.0	1
11	Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 46, 354-362.	4.3	8
12	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. <i>CNS Spectrums</i> , 2019, 24, 441-452.	1.2	15
13	Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases. <i>American Journal of Therapeutics</i> , 2018, 25, e218-e223.	0.9	60
14	A switch-variant model integrates the functions of an autoimmune variant of the phosphatase PTPN22. <i>Science Signaling</i> , 2018, 11, .	3.6	12
15	Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia: A Nation-Wide Register Study. <i>Schizophrenia Bulletin</i> , 2018, 44, 93-100.	4.3	11
16	Effect of a physical activity intervention on suPAR levels: A randomized controlled trial. <i>Journal of Science and Medicine in Sport</i> , 2018, 21, 286-290.	1.3	10
17	Pregabalin for anxiety in patients with schizophrenia â€” A randomized, double-blind placebo-controlled study. <i>Schizophrenia Research</i> , 2018, 195, 260-266.	2.0	8
18	Schizophrenia-associated mt-DNA SNPs exhibit highly variable haplogroup affiliation and nuclear ancestry: Bi-genomic dependence raises major concerns for link to disease. <i>PLoS ONE</i> , 2018, 13, e0208828.	2.5	15

#	ARTICLE	IF	CITATIONS
19	Complex spatio-temporal distribution and genomic ancestry of mitochondrial DNA haplogroups in 24,216 Danes. PLoS ONE, 2018, 13, e0208829.	2.5	5
20	In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1324-1331.	1.9	18
21	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry, 2017, 16, 77-89.	10.4	156
22	Minimal T-wave representation and its use in the assessment of drug arrhythmogenicity. , 2017, 22, e12413.		3
23	Diabetic ketoacidosis and diabetes associated with antipsychotic exposure among a previously diabetes-naïve population with schizophrenia: a nationwide nested case-control study. Diabetologia, 2017, 60, 1678-1690.	6.3	14
24	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. JAMA Psychiatry, 2017, 74, 719.	11.0	135
25	Association between bystander cardiopulmonary resuscitation and redeemed prescriptions for antidepressants and anxiolytics in out-of-hospital cardiac arrest survivors. Resuscitation, 2017, 115, 32-38.	3.0	5
26	Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review. Journal of Psychopharmacology, 2017, 31, 397-405.	4.0	13
27	Antipsychotic-associated psoriatic rash - a case report. BMC Psychiatry, 2017, 17, 242.	2.6	7
28	Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases. BMC Psychiatry, 2016, 16, 70.	2.6	21
29	Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology, 2016, 233, 3663-3672.	3.1	28
30	Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics. JAMA Psychiatry, 2016, 73, 247.	11.0	189
31	Abuse Potential of Pregabalin. CNS Drugs, 2016, 30, 9-25.	5.9	104
32	The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology, 2016, 233, 741-750.	3.1	51
33	Worldwide Differences in Regulations of Clozapine Use. CNS Drugs, 2016, 30, 149-161.	5.9	139
34	Cardiovascular safety of antipsychotics: a clinical overview. Expert Opinion on Drug Safety, 2016, 15, 679-688.	2.4	44
35	Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. European Neuropsychopharmacology, 2015, 25, 1669-1676.	0.7	27
36	Cardiac effects of sertindole and quetiapine: Analysis of ECGs from a randomized double-blind study in patients with schizophrenia. European Neuropsychopharmacology, 2015, 25, 303-311.	0.7	15

#	ARTICLE	IF	CITATIONS
37	Unrecognised myocardial infarction in patients with schizophrenia. <i>Acta Neuropsychiatrica</i> , 2015, 27, 106-112.	2.1	29
38	The T-peakâ€“T-end Interval as a Marker of Repolarization Abnormality: A Comparison with the QT Interval for Five Different Drugs. <i>Clinical Drug Investigation</i> , 2015, 35, 717-724.	2.2	14
39	Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 627-636.	4.3	44
40	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. <i>Nature Communications</i> , 2014, 5, 4757.	12.8	153
41	Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 4-14.	2.7	7
42	Risk factors for suicide among 34,671 patients with psychotic and non-psychotic severe depression. <i>Journal of Affective Disorders</i> , 2014, 156, 119-125.	4.1	50
43	Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. <i>European Heart Journal</i> , 2014, 35, 1306-1315.	2.2	103
44	Rapid clozapine titration in treatment-refractory bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 168-172.	4.1	48
45	Termination of Clozapine Treatment Due to Medical Reasons. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 603-613.	2.2	193
46	Predictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 678-683.	1.4	75
47	Risk Factors for Ileus in Patients with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 592-598.	4.3	113
48	Augmenting Clozapine With Sertindole. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 173-178.	1.4	37
49	Hematological clozapine monitoring with a point-of-care device: A randomized cross-over trial. <i>European Neuropsychopharmacology</i> , 2012, 22, 401-405.	0.7	15
50	Geographical and temporal variations in clozapine prescription for schizophrenia. <i>European Neuropsychopharmacology</i> , 2012, 22, 818-824.	0.7	71
51	Realâ€“world effectiveness of clozapine in patients with bipolar disorder: results from a 2â€“year mirrorâ€“image study. <i>Bipolar Disorders</i> , 2012, 14, 863-869.	1.9	52
52	Safety and tolerability of antipsychotic polypharmacy. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 527-542.	2.4	163
53	Characteristics and predictors of long-term institutionalization in patients with schizophrenia. <i>Schizophrenia Research</i> , 2011, 131, 120-126.	2.0	51
54	Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics. <i>CNS Drugs</i> , 2011, 25, 473-490.	5.9	115

#	ARTICLE	IF	CITATIONS
55	Determinants of Poor Dental Care in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 140-143.	2.2	52
56	10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 356-366.	4.5	69
57	Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2010, 35, 1997-2004.	5.4	183
58	Increased use of antibiotics in patients treated with clozapine. <i>European Neuropsychopharmacology</i> , 2009, 19, 483-486.	0.7	33
59	Sertindole causes distinct electrocardiographic T-wave morphology changes. <i>European Neuropsychopharmacology</i> , 2009, 19, 702-707.	0.7	37